UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Systemic Immunologic Effects of Definitive Radiation in Head and Neck Cancer

International journal of radiation oncology, biology, physics, 2016-03, Vol.94 (4), p.864-864

2016

Volltextzugriff (PDF)

Efficacy of pembrolizumab in patients with advanced mucosal melanoma enrolled in the KEYNOTE-001, 002, and 006 studies

European journal of cancer (1990), 2017-02, Vol.72, p.S123-S123

2017

Volltextzugriff (PDF)

23LBA An open-label, randomized, phase 2 study of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064)

European journal of cancer (1990), 2015-09, Vol.51, p.S721-S721

2015

Volltextzugriff (PDF)

513 Safety, activity and biomarkers of atezolizumab (MPDL3280A) with platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): A Phase Ib study

European journal of cancer (1990), 2015-09, Vol.51, p.S107-S108

2015

Volltextzugriff (PDF)

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

Annals of oncology, 2019-04, Vol.30 (4), p.582-588

2019

Volltextzugriff (PDF)

3303 Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067)

European journal of cancer (1990), 2015-09, Vol.51, p.S664-S665

2015

Volltextzugriff (PDF)

24LBA Safety data from the phase 1b part of the MASTERKEY-265 study combining talimogene laherparepvec (T-VEC) and pembrolizumab for unresectable stage IIIB-IV melanoma

European journal of cancer (1990), 2015-09, Vol.51, p.S722-S722

2015

Volltextzugriff (PDF)

P0116 Updated clinical efficacy of the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in 411 patients with melanoma

European journal of cancer (1990), 2015-07, Vol.51, p.e24-e24

2015

Volltextzugriff (PDF)

Pembrolizumab (Pembro; Mk-3475) for Advanced Melanoma (Mel): Randomized Comparison of Two Dosing Schedules

Annals of oncology, 2014-09, Vol.25, p.v1

2014

Volltextzugriff (PDF)

Melanoma Brain Metastases Treated With Brain-directed Radiation Followed by Ipilimumab

International journal of radiation oncology, biology, physics, 2012-11, Vol.84 (3), p.S287-S287

2012

Volltextzugriff (PDF)

140 Relationship between programmed death ligand 1 (PD-L1) expression and clinical outcome in patients (pts) with melanoma (MEL) treated with pembrolizumab (pembro; MK-3475)

European journal of cancer (1990), 2014-11, Vol.50, p.48-49

2014

Volltextzugriff (PDF)

Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma

Annals of oncology, 2015-04, Vol.26 (4), p.812-817

2015

Volltextzugriff (PDF)

PD-L1 expression in nonclear-cell renal cell carcinoma

Annals of oncology, 2014-11, Vol.25 (11), p.2178-2184

2014

Volltextzugriff (PDF)

Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial

Annals of oncology, 2017-06, Vol.28 (6), p.1380-1387

2017

Volltextzugriff (PDF)

Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer

Annals of oncology, 2021-12, Vol.32 (12), p.1597-1607

2021

Volltextzugriff (PDF)

Stereotactic Radiosurgery in the Initial Management of Melanoma Brain Metastases

International journal of radiation oncology, biology, physics, 2011, Vol.81 (2), p.S642-S643

2011

Volltextzugriff (PDF)

9306 ORAL Safety and Efficacy of Ipilimumab-treated Patients With Melanoma and Brain Metastases

European journal of cancer (1990), 2011, Vol.47, p.S654-S654

2011

Volltextzugriff (PDF)

1071TiP Phase I study of the investigational CD228 x 4-1BB costimulatory antibody anticalin bispecific SGN-BB228 (PF-08046049) in advanced melanoma and other solid tumors

Annals of oncology, 2024-09, Vol.35, p.S709-S709

2024

Volltextzugriff (PDF)

Response Rate And Local Recurrence After Concurrent Immune Checkpoint Therapy And Radiation For Non-Small Cell Lung Cancer And Melanoma Brain Metastases

International journal of radiation oncology, biology, physics, 2020-11, Vol.108 (3), p.e709-e709

2020

Volltextzugriff (PDF)

Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response

Annals of oncology, 2019-04, Vol.30 (4), p.589-596

2019

Volltextzugriff (PDF)

New Toxicities of Immune Checkpoint Modulators

Annals of oncology, 2013-03, Vol.24, p.i7-i7

Hodi, F.S.

2013

Volltextzugriff (PDF)

1092P Nivolumab plus relatlimab vs nivolumab in previously untreated metastatic or unresectable melanoma: 3-year subgroup analyses from RELATIVITY-047

Annals of oncology, 2024-09, Vol.35, p.S723-S724

2024

Volltextzugriff (PDF)

Radiation and Immune Checkpoint Inhibitor Therapy in Mucosal Melanoma

International journal of radiation oncology, biology, physics, 2020-11, Vol.108 (3), p.e12-e12

2020

Volltextzugriff (PDF)

1135P Comparison of intracranial (IC) response assessment criteria in patients (pts) with melanoma brain metastases (MBM) treated with combination nivolumab (NIVO) plus ipilimumab (IPI) in CheckMate 204

Annals of oncology, 2023-10, Vol.34, p.S680-S681

2023

Volltextzugriff (PDF)

1103P Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year subgroup analyses from RELATIVITY-047

Annals of oncology, 2023-10, Vol.34, p.S664-S665

2023

Volltextzugriff (PDF)

1 – 25 von 80

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(80)
Mit Volltextzugriff
(77)

Publikationsform

Artikel
(80)

Sprache

Englisch
(78)
Französisch
(2)

Erscheinungsjahr

n.n

Thema

Hematology, Oncology And Palliative Medicine
(12)
Life Sciences & Biomedicine
(8)
Oncology
(8)
Science & Technology
(8)
Humans
(6)
Immunotherapy
(4)
Melanoma
(4)
Original
(4)
Adult
(3)
Aged
(3)
Female
(3)
Male
(3)
Middle Aged
(3)
Pd-1
(3)
Radiology
(3)
Editor's Choice
(2)
Follow-Up Studies
(2)
Ipilimumab
(2)
Kaplan-Meier Estimate
(2)
Melanoma - Drug Therapy
(2)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Electronic Journals Library
(61)
Journals@Ovid Complete
(60)
Ingenta E-Journals
(20)
Elsevier ScienceDirect Journals Complete
(19)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(16)
MEDLINE
(6)
IngentaConnect Journals
(3)

2 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

3 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Systemic Immunologic Effects of Definitive Radiation in Head and Neck Cancer

Efficacy of pembrolizumab in patients with advanced mucosal melanoma enrolled in the KEYNOTE-001, 002, and 006 studies

23LBA An open-label, randomized, phase 2 study of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064)

513 Safety, activity and biomarkers of atezolizumab (MPDL3280A) with platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): A Phase Ib study

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

3303 Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067)

24LBA Safety data from the phase 1b part of the MASTERKEY-265 study combining talimogene laherparepvec (T-VEC) and pembrolizumab for unresectable stage IIIB-IV melanoma

P0116 Updated clinical efficacy of the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in 411 patients with melanoma

Pembrolizumab (Pembro; Mk-3475) for Advanced Melanoma (Mel): Randomized Comparison of Two Dosing Schedules

Melanoma Brain Metastases Treated With Brain-directed Radiation Followed by Ipilimumab

140 Relationship between programmed death ligand 1 (PD-L1) expression and clinical outcome in patients (pts) with melanoma (MEL) treated with pembrolizumab (pembro; MK-3475)

Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma

PD-L1 expression in nonclear-cell renal cell carcinoma

Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial

Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer

Stereotactic Radiosurgery in the Initial Management of Melanoma Brain Metastases

9306 ORAL Safety and Efficacy of Ipilimumab-treated Patients With Melanoma and Brain Metastases

1071TiP Phase I study of the investigational CD228 x 4-1BB costimulatory antibody anticalin bispecific SGN-BB228 (PF-08046049) in advanced melanoma and other solid tumors

Response Rate And Local Recurrence After Concurrent Immune Checkpoint Therapy And Radiation For Non-Small Cell Lung Cancer And Melanoma Brain Metastases

Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response

New Toxicities of Immune Checkpoint Modulators

1092P Nivolumab plus relatlimab vs nivolumab in previously untreated metastatic or unresectable melanoma: 3-year subgroup analyses from RELATIVITY-047

Radiation and Immune Checkpoint Inhibitor Therapy in Mucosal Melanoma

1135P Comparison of intracranial (IC) response assessment criteria in patients (pts) with melanoma brain metastases (MBM) treated with combination nivolumab (NIVO) plus ipilimumab (IPI) in CheckMate 204

1103P Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year subgroup analyses from RELATIVITY-047

Suchergebnisse filtern